Skip to the answer

Insulin Lispro Injection

Insulin lispro is a rapid-acting insulin analog used to improve blood sugar control in adults and children with diabetes mellitus.

Brand names AdmelogHumalogHumalog Mix50/50Humalog Mix75/25Lyumjev +8 more
Drug class Insulin Analog
Rx Form 1
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 11 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

Insulin Lispro Injection at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Insulin lispro is a rapid-acting mealtime insulin for type 1 and type 2 diabetes. It helps muscle and fat cells take up glucose and tells the liver to stop releasing more, and on the U.S. market since about 1996, it is one of the most familiar mealtime insulins, usually paired with a long-acting background insulin. Most people tolerate it well, and what they notice is occasional low blood sugar, redness or itching where they inject, and some weight gain. The one thing to look for is low blood sugar (hypoglycemia), which can strike suddenly and cause seizures, so never inject it and then skip the meal.

Clinical pearls

  • Inject within 15 minutes before a meal or right after eating, because it starts working quickly and is meant to match food.
  • Check the label before every injection, since mix-ups with other insulins happen, and never share a pen, even with a new needle.
  • Rotate sites across the abdomen, thigh, upper arm and buttocks, since reusing one spot causes lumpy skin that absorbs insulin unevenly.
  • Beta-blockers can hide the shaky, racing-heart warning signs of low blood sugar, so check readings more often if you take one.
How we write & review this content — our editorial policy →
How you get itPrescription only
Comes asInjection
Earliest FDA record1996
Companies listing it with the FDA4
FDA label last updatedJun 16, 2026
FDA’s strongest warning (boxed)None on the label

Patient information guide A plain-language walkthrough of Insulin Lispro Injection, written from its FDA label.

What Insulin Lispro Injection is used for

▾

Insulin lispro injection is a rapid-acting insulin analog used to help control blood sugar in people with diabetes mellitus. Specific approved uses across products include:

  • Admelog (subcutaneous injection) improves glycemic control in adults and children with diabetes mellitus, including children 3 years and older with type 1 diabetes
  • Humalog (subcutaneous injection, insulin pump, or intravenous infusion) improves glycemic control in patients with diabetes mellitus
  • Humalog Mix75/25 (subcutaneous injection) improves glycemic control in adults with diabetes mellitus; its fixed ratio of rapid- and intermediate-acting insulin does not allow separate adjustment of basal and mealtime doses

How Insulin Lispro Injection works

▾

Insulin lispro is a modified form of human insulin that works the same way natural insulin does, but acts faster. It signals muscle and fat cells to absorb glucose from the blood, tells the liver to stop making extra glucose, and prevents the breakdown of fat and protein — all of which help keep blood sugar levels in a healthy range.

Because of small structural changes in the molecule, insulin lispro is absorbed more quickly from the injection site than regular human insulin, giving it a faster onset and shorter duration of action. This makes it well-suited for controlling blood sugar around mealtimes.

Insulin Lispro Injection dosage

▾

Insulin lispro is given by subcutaneous (under-the-skin) injection, by continuous infusion via an insulin pump, or in clinical settings by intravenous infusion. Subcutaneous injections are typically given within 15 minutes before a meal or immediately after a meal.

  • Inject into the abdomen, thigh, upper arm, or buttocks — and rotate sites each time
  • Humalog U-100 can be used in an insulin pump; Humalog U-200 must NOT be used in a pump or given intravenously
  • Your exact dose is individualized by your prescriber based on your blood sugar readings, eating habits, activity level, and other factors
  • If you miss a dose or your pump malfunctions, contact your healthcare provider — do not guess on a replacement dose

Dosing details from the FDA-approved label

From the Insulin Lispro Injection prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Subcutaneous injection (HUMALOG U-100 or U-200)
    • Administer within fifteen minutes before a meal or immediately after a meal by injection into the subcutaneous tissue of the abdominal wall, thigh, upper arm, or buttocks
    • Generally used in regimens with an intermediate- or long-acting insulin
    • Maximum: HUMALOG U-100 KwikPen, U-100 Tempo Pen, and U-200 KwikPen: 60 units per injection; HUMALOG U-100 Junior KwikPen: 30 units per injection
    • Dosage individualized based on route of administration, metabolic needs, blood glucose monitoring results and glycemic control goal
  • Diluted HUMALOG U-100 for subcutaneous injection
    • Dilute one part HUMALOG U-100 to nine parts diluent (equivalent to U-10) or one part diluent (equivalent to U-50) using Sterile Diluent for HUMALOG, ONLY under medical supervision
    • Diluted insulin may be stored for 28 days refrigerated at 41°F (5°C) and 14 days at room temperature up to 86°F (30°C)
  • Continuous subcutaneous infusion (insulin pump), HUMALOG U-100 only
    • Administer by continuous subcutaneous infusion in a region recommended in the pump manufacturer's instructions
    • Change HUMALOG U-100 in the pump reservoir at least every 7 days or according to the pump user manual, whichever is shorter
    • Do not dilute or mix; do not administer U-200; do not expose reservoir to temperatures greater than 98.6°F (37°C)
  • Intravenous administration, HUMALOG U-100 only
    • Dilute HUMALOG U-100 to concentrations from 0.1 unit/mL to 1.0 unit/mL using 0.9% Sodium Chloride Injection, USP, and administer ONLY under medical supervision with close monitoring of blood glucose and potassium
    • Infusion bags stable refrigerated (2° to 8°C [36° to 46°F]) for 48 hours, then up to an additional 48 hours at room temperature; do not administer U-200 intravenously
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION See Full Prescribing Information for important administration instructions. ( 2.1 , 2.2 , 2.3 , 2.4 ) Subcutaneous injection ( 2.2 ): Administer HUMALOG ® U-100 or U-200 by subcutaneous injection into the abdominal wall, thigh, upper arm, or buttocks within 15 minutes before a meal or immediately after a meal. Rotate injection sites to reduce risk of lipodystrophy and localized cutaneous amyloidosis. Continuous subcutaneous infusion (Insulin Pump) ( 2.2 ): Refer to the insulin infusion pump user manual to see if HUMALOG can be used. Use in accordance with the insulin pump instructions for use. Administer HUMALOG U-100 by continuous subcutaneous infusion using an insulin pump in a region recommended in the instructions from the pump manufacturer. Rotate infusion sites to reduce risk of lipodystrophy and localized cutaneous amyloidosis. DO NOT administer HUMALOG U-200 by continuous subcutaneous infusion. Intravenous Infusion ( 2.2 ): Administer HUMALOG U-100 by intravenous infusion ONLY after dilution and under medical supervision. DO NOT administer HUMALOG U-200 by intravenous infusion. The dosage of HUMALOG must be individualized based on the route of administration and the individual's metabolic needs, blood glucose monitoring results and glycemic control goal. ( 2.3 ) Do not perform dose conversion when using the HUMALOG U-100 or U-200 prefilled pens. The dose window shows the number of insulin units to be delivered and no conversion is needed. ( 2.1 , 2.3 ) Do not mix HUMALOG U-200 with any other insulin. ( 2.4 ) 2.1 Important Administration Instructions Always check insulin labels before administration [see Warnings and Precautions ( 5.4 )] . Inspect HUMALOG visually before use. It should appear clear and colorless. Do not use HUMALOG if particulate matter or coloration is seen. Use HUMALOG prefilled pens with caution in patients with visual impairment that may rely on audible clicks to dial their dose. Do NOT mix HUMALOG U-100 with other insulins when using a continuous subcutaneous infusion pump. Do NOT transfer HUMALOG U-200 from the prefilled pen to a syringe for administration [see Warnings and Precautions ( 5.4 )] . Do NOT perform dose conversion when using any HUMALOG U-100 or U-200 prefilled pens. The dose window shows the number of insulin units to be delivered and no conversion is needed.

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Insulin Lispro Injection side effects

▾

Like all insulins, insulin lispro can cause a range of side effects, most commonly related to blood sugar changes:

Common side effects

  • Low blood sugar (hypoglycemia) — the most common reaction
  • Redness, swelling, or itching at the injection site
  • Skin thickening or dimpling at injection sites (lipodystrophy)
  • Rash or itching (pruritus)
  • Weight gain
  • Swelling in the hands or feet (peripheral edema)
  • Nasopharyngitis (common cold symptoms)
  • Upper respiratory tract infection
  • Infusion site reactions including redness when used with an insulin pump

When to get medical help

  • Severe low blood sugar (hypoglycemia): seizures, loss of consciousness, or extreme confusion — seek emergency help immediately
  • Severe allergic reaction (anaphylaxis): whole-body rash, trouble breathing, wheezing, rapid heartbeat, or sudden drop in blood pressure — call 911
  • Low potassium (hypokalemia): muscle weakness, irregular heartbeat — call your doctor
  • Signs of heart failure if you also take a thiazolidinedione (TZD) diabetes pill: sudden weight gain, swelling, or shortness of breath — contact your doctor
  • High blood sugar or diabetic ketoacidosis from insulin pump failure: nausea, vomiting, fruity breath, high glucose readings — seek medical care promptly

Severe allergic reactions (anaphylaxis), dangerously low blood sugar, and low potassium (hypokalemia) are rare but serious — seek emergency care immediately if these occur.

Insulin Lispro Injection warnings and precautions

▾
  • Hypoglycemia (low blood sugar) is the most common and most serious risk — it can cause seizures, unconsciousness, and death. Risk is highest around peak insulin action, after missed meals, with extra exercise, or when changing your regimen.
  • Never share pens, cartridges, or syringes with another person, even with a new needle — doing so can transmit serious bloodborne infections.
  • Medication errors can occur if insulin labels are not checked before every injection. Do not transfer Humalog U-200 from the pen to a syringe — the syringe markings are wrong for U-200 and can cause a dangerous overdose.
  • Hypokalemia (low potassium): Insulin shifts potassium into cells; low potassium can cause life-threatening heart rhythm problems. Your doctor may monitor your potassium levels.
  • Severe allergic reactions including anaphylaxis can occur — stop the insulin and get emergency help if you develop trouble breathing, widespread rash, or a racing heart.
  • Insulin pump users: A pump or infusion set malfunction can quickly lead to high blood sugar and diabetic ketoacidosis. Always have a backup injection plan.
  • Thiazolidinedione (TZD) diabetes pills combined with insulin can cause fluid retention that may worsen or trigger heart failure — watch for swelling and shortness of breath.

Insulin Lispro Injection interactions

▾

Several common medications and substances can affect how insulin lispro works in your body:

  • Drugs that increase hypoglycemia risk: other diabetes medications, ACE inhibitors, ARBs (blood pressure drugs), fibrates, fluoxetine, MAO inhibitors, salicylates (like aspirin), pentoxifylline, pramlintide, octreotide, and sulfonamide antibiotics — may require a lower insulin dose
  • Drugs that reduce insulin's effectiveness: corticosteroids, atypical antipsychotics (e.g., olanzapine, clozapine), diuretics, estrogens, oral contraceptives, thyroid hormones, protease inhibitors, glucagon, isoniazid, niacin, danazol, somatropin, and sympathomimetics (e.g., albuterol, epinephrine) — may require a higher insulin dose
  • Drugs with unpredictable effects: alcohol, beta-blockers, clonidine, lithium salts, and pentamidine — blood sugar can go either direction
  • Drugs that hide low blood sugar symptoms: beta-blockers, clonidine, guanethidine, and reserpine — you may not feel the usual warning signs of hypoglycemia
  • Thiazolidinediones (TZD pills): can cause fluid buildup and increase risk of heart failure when combined with insulin

Interactions listed in the FDA-approved label

From the Insulin Lispro Injection prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics: May increase the risk of hypoglycemia. Dose adjustment and increased frequency of glucose monitoring may be required.
  • Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens, protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones: May decrease the blood glucose lowering effect. Dose adjustment and increased frequency of glucose monitoring may be required.
  • Alcohol, beta-blockers, clonidine, lithium salts: May increase or decrease the blood glucose lowering effect. Dose adjustment and increased frequency of glucose monitoring may be required.
  • Pentamidine: May cause hypoglycemia, which may sometimes be followed by hyperglycemia. Dose adjustment and increased frequency of glucose monitoring may be required.
  • Beta-blockers, clonidine, guanethidine, reserpine: May blunt signs and symptoms of hypoglycemia. Increased frequency of glucose monitoring may be required.
Read the label’s full interactions text

7 DRUG INTERACTIONS Table 1 below presents clinically significant drug interactions with HUMALOG Mix75/25. Table 1: Clinically Significant Drug Interactions with HUMALOG Mix75/25 Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when HUMALOG Mix75/25 is co-administered with these drugs. Drugs that May Decrease the Blood Glucose Lowering Effect of HUMALOG Mix75/25 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when HUMALOG Mix75/25 is co-administered with these drugs. Drugs that May Increase or Decrease the Blood Glucose Lowering Effect of HUMALOG Mix75/25 Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when HUMALOG Mix75/25 is co-administered with these drugs. Drugs that May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine, and reserpine. Intervention: Increased frequency of glucose monitoring may be required when HUMALOG Mix75/25 is co-administered with these drugs.

Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿242 supplements and herbs with documented Insulin Lispro Injection interactions, ranked by severity Check Insulin Lispro Injection against a supplement or herb →

Before taking Insulin Lispro Injection

▾
  • Do not use insulin lispro if your blood sugar is already low (hypoglycemia)
  • Do not use if you have a known allergy to insulin lispro or any ingredient in the product
  • Tell your doctor if you have kidney disease — reduced kidney function increases sensitivity to insulin and hypoglycemia risk
  • Tell your doctor if you have liver disease — liver impairment can raise circulating insulin levels and increase hypoglycemia risk
  • If you are pregnant or planning to become pregnant, tell your doctor — poorly controlled diabetes in pregnancy increases risks for both mother and baby, but published data do not show an association between insulin lispro and major birth defects
  • If you are breastfeeding, discuss with your doctor — insulin lispro passes into breast milk; no adverse effects in breastfed infants have been reported in the literature
  • Admelog's safety and effectiveness in children have been established for patients 3 years and older with type 1 diabetes
  • Older adults (65+) can use insulin lispro; blood sugar control and hypoglycemia rates are similar to younger adults, but careful monitoring remains important
  • Patients with visual impairment should use prefilled pens with caution, as audible clicks are needed to dial the dose accurately

Insulin Lispro Injection overdose

▾

Too much insulin lispro causes hypoglycemia (dangerously low blood sugar) and can also lower potassium levels (hypokalemia). Mild low blood sugar can usually be treated by eating or drinking something sugary. Severe cases — especially with seizures, loss of consciousness, or neurological symptoms — require glucagon (an emergency injection) or intravenous glucose, and should be treated by medical professionals. Because blood sugar can drop again after initial recovery, observation and continued carbohydrate intake may be needed.

What Insulin Lispro Injection does in the body

▾

Insulin lispro starts lowering blood sugar more quickly and its effect wears off sooner compared to regular human insulin when injected under the skin. One unit of insulin lispro has the same overall glucose-lowering power as one unit of regular human insulin. The timing of its peak effect can vary between individuals and even in the same person from day to day, depending on the injection site, blood flow, exercise, and other factors. When given intravenously under medical supervision, Humalog U-100 brought blood sugar into a target range within about two hours on average in a clinical study of patients with type 1 diabetes.

How your body processes Insulin Lispro Injection

▾

After a subcutaneous injection, insulin lispro is absorbed faster than regular human insulin — peak blood levels are typically reached within 30 to 90 minutes, compared to 50 to 120 minutes for regular insulin. Its half-life (the time for half the drug to leave the body) after subcutaneous injection is about 1 hour, shorter than regular insulin's roughly 1.5 hours. Absorption is fastest from the abdomen, and slightly slower from the thigh or upper arm. The body metabolizes insulin lispro the same way it processes regular human insulin, and it is cleared from the body similarly whether given subcutaneously or intravenously.

How to store Insulin Lispro Injection

▾

Dispense in the original sealed carton with the enclosed Instructions for Use. Protect from direct heat and light. Do not freeze and do not use if it has been frozen.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

242

Supplements & herbs that interact with Insulin Lispro Injection

242 supplements and herbal products have documented interactions with Insulin Lispro Injection in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 2
  • Moderate · 211
  • Minor · 29
CHELATION THERAPY PRODUCTS Major SIBERIAN COCKLEBUR Major ACAI Moderate AFRICAN WILD POTATO Moderate AGARICUS MUSHROOM Moderate AGMATINE Moderate AGRIMONY Moderate ALFALFA Moderate +234 more
Every supplement checked against Insulin Lispro Injection — ranked by severity The full interaction hub: 2 major · 211 moderate · 29 minor · every one linked to its full report. Check Insulin Lispro Injection against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

2

Nutrient depletion considerations

Insulin Lispro Injection has been associated with lower levels of 2 nutrients in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.

COENZYME Q10 Insignificant Depletion MAGNESIUM Insignificant Depletion
See the full Insulin Lispro Injection nutrient depletion report

Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.

Insulin Lispro Injection: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Insulin Lispro Injection — the kind of thing our pharmacy team would talk through with you at the counter.

What exactly does insulin lispro do, and why did my doctor prescribe it?

▾
Insulin lispro is a fast-acting insulin that helps your body manage blood sugar around mealtimes. It works by helping your muscles and fat cells absorb glucose from your blood, while signaling your liver to stop releasing extra sugar. Your doctor most likely prescribed it because you have type 1 or type 2 diabetes and need help keeping your blood sugar in a healthy range, especially after eating.

When exactly should I inject this insulin — before or after I eat?

▾
For subcutaneous injections, you should inject insulin lispro within 15 minutes before a meal or immediately after a meal. Because it acts quickly, timing really matters — injecting too early without eating, or forgetting to eat after injecting, can cause your blood sugar to drop dangerously low. Always follow the specific instructions your prescriber has given you, since your regimen may be different.

What does low blood sugar feel like, and what should I do if it happens?

▾
Low blood sugar (hypoglycemia) can feel like shakiness, sweating, confusion, rapid heartbeat, or sudden hunger. Mild episodes can usually be treated by eating or drinking something with sugar. If the symptoms are severe — such as seizures or loss of consciousness — someone needs to give you a glucagon emergency kit and call 911 right away. Always have a fast-acting sugar source nearby, and make sure family members know what to do in an emergency.

Can I share my insulin pen with a family member who also has diabetes?

▾
Absolutely not — never share your pen, cartridge, or syringe with anyone else, even a family member, and even if you use a new needle. Sharing carries a real risk of passing bloodborne infections between people. Each person needs their own dedicated device.

Are there any common medications or foods I should watch out for while using insulin lispro?

▾
Yes, several things can affect how your insulin works. Alcohol, beta-blockers (used for blood pressure or heart conditions), and some other medications can make your blood sugar go unpredictably high or low. Some blood pressure medications, antidepressants, and other diabetes drugs can increase the risk of low blood sugar. Steroids, certain antipsychotics, and diuretics can make the insulin less effective. Give your pharmacist and doctor a full list of everything you take — including over-the-counter medicines — so they can flag any concerns.

Is it safe to use insulin lispro during pregnancy?

▾
Managing blood sugar well during pregnancy is very important — poorly controlled diabetes raises risks for both you and your baby. Published studies have not found that insulin lispro causes major birth defects or miscarriage, but every pregnancy is unique. If you are pregnant, planning to become pregnant, or breastfeeding, talk with your doctor right away so your insulin regimen can be carefully monitored and adjusted as needed.

Is Insulin Lispro Injection available over the counter?

▾
No. Insulin Lispro Injection is a prescription medicine: every Insulin Lispro Injection product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Insulin Lispro Injection first available?

▾
The earliest FDA record we hold for Insulin Lispro Injection is from 1996: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Insulin Lispro Injection was first used.

Who makes Insulin Lispro Injection?

▾
4 companies currently list Insulin Lispro Injection products in the FDA's NDC Directory, including Eli Lilly and Company, A-S Medication Solutions, Sanofi-Aventis U.S. LLC. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Insulin Lispro Injection on HelloPharmacist

📊Insulin Lispro Injection supplement interactions242 checked — ranked by severity 🌿Drug & Supplement CheckerInsulin Lispro Injection vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Insulin Lispro Injection NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Insulin Lispro Injection Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Insulin Lispro Injection forms and strengths (how it comes)

Insulin Lispro Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Injection

By injection · Into a vein · Under the skin
Brands Admelog Humalog
How this form is used
What it may be used for
  • Admelog (subcutaneous injection) is used to improve glycemic control in adults and children (3 years and older) with diabetes mellitus
  • Humalog U-100 (subcutaneous injection or continuous subcutaneous infusion via insulin pump) is used to improve glycemic control in patients with diabetes mellitus
  • Humalog U-100 (intravenous infusion) is used for glycemic control under medical supervision only
  • Humalog Mix75/25 (subcutaneous injection) is used to improve glycemic control in adults with diabetes mellitus, with fixed rapid- and intermediate-acting proportions
Important instructions
  • Admelog and Humalog U-100 or U-200 subcutaneous injections are given into the abdomen, thigh, upper arm, or buttocks within 15 minutes before or immediately after a meal; rotate injection sites regularly
  • Humalog U-100 may be used in a continuous subcutaneous insulin infusion pump; do NOT use Humalog U-200 in an insulin pump
  • Humalog U-100 may be given intravenously ONLY after dilution and under close medical supervision with monitoring of blood glucose and potassium; do NOT administer Humalog U-200 intravenously
  • Sterile Diluent for Humalog may be used to dilute Humalog U-100 for subcutaneous injection only, under medical supervision
Available strengths 4 strengths
100 U/mL 100 [IU]/mL INSULIN LISPRO 100 U/mL 200 [IU]/mL
89 FDA-listed product records ⓘ

Insulin Lispro Injection on the U.S. market: products, makers and brands

How Insulin Lispro Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

4 companies list 22 Insulin Lispro Injection product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 1996. Brand names on the directory include Admelog, Humalog, Humalog Mix50/50 and 10 more; the rest are generics.

1
Dose forms ⓘ
4
Labelers (makers, repackagers, distributors)
13
Brand names
22
FDA-listed product records ⓘ
1996
Earliest FDA record ⓘ
Eli Lilly and Company59%
A-S Medication Solutions23%
Sanofi-Aventis U.S. LLC14%
Remedyrepack Inc.5%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How widely Insulin Lispro Injection is used (Medicaid data)

A general measure of how commonly Insulin Lispro Injection is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Insulin Lispro Injection is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

2,318,237
Medicaid prescriptions filled (Q1–Q4 2025)
$466.4M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Insulin Lispro Injection prescribed? Of the 1,601 medications we measure, Insulin Lispro Injection ranks #96 by Medicaid prescriptions — more than 94% of them.

Where Insulin Lispro Injection ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #96 of 1,601
#91 Olanzapine 2,565,436 Rx #92 Naproxen 2,556,513 Rx #93 Methylprednisolone Inj... 2,550,742 Rx #94 Spironolactone 2,528,169 Rx #95 Oseltamivir 2,322,109 Rx #96 Insulin Lispro Injecti... 2,318,237 Rx #97 Methocarbamol 2,261,221 Rx #98 Tizanidine 2,254,693 Rx #99 Cefdinir 2,236,722 Rx #100 Sulfamethoxazole / Tri... 2,217,156 Rx #101 Carvedilol 2,202,041 Rx

Utilization by Insulin Lispro Injection product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 3 mL / 100 units/mL pen injector is the most-dispensed Insulin Lispro Injection product — about 52% of these Medicaid prescriptions.

3 ML insulin lispro 100 UNT/ML Pen Injector Most dispensed

1,199,940 Medicaid prescriptions (Q1–Q4 2025) 52% of Insulin Lispro Injection prescriptions shown $235.8M gross reimbursement (before rebates) ≈ $197 per prescription (gross)

Summed across the 3 of 11 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1652639

insulin lispro 100 UNT/ML Injectable Solution

905,733 Medicaid prescriptions (Q1–Q4 2025) 39% of Insulin Lispro Injection prescriptions shown $116.6M gross reimbursement (before rebates) ≈ $129 per prescription (gross)

Summed across the 8 of 61 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 242120

0.5 UNT Doses 3 ML insulin lispro 100 UNT/ML Pen Injector

138,473 Medicaid prescriptions (Q1–Q4 2025) 6% of Insulin Lispro Injection prescriptions shown $26.7M gross reimbursement (before rebates) ≈ $193 per prescription (gross)

Summed across the 2 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1926331

3 ML insulin lispro 200 UNT/ML Pen Injector

45,754 Medicaid prescriptions (Q1–Q4 2025) 2% of Insulin Lispro Injection prescriptions shown $71.1M gross reimbursement (before rebates) ≈ $1,554 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1652239

3 ML insulin lispro 100 UNT/ML Cartridge

14,068 Medicaid prescriptions (Q1–Q4 2025) <1% of Insulin Lispro Injection prescriptions shown $3.4M gross reimbursement (before rebates) ≈ $238 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1652644

insulin lispro-aabc 100 UNT/ML Injectable Solution

7,970 Medicaid prescriptions (Q1–Q4 2025) <1% of Insulin Lispro Injection prescriptions shown $7M gross reimbursement (before rebates) ≈ $873 per prescription (gross)

Summed across the 1 of 9 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2380231

3 ML insulin lispro-aabc 100 UNT/ML Pen Injector

4,944 Medicaid prescriptions (Q1–Q4 2025) <1% of Insulin Lispro Injection prescriptions shown $3.6M gross reimbursement (before rebates) ≈ $732 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2380259

3 ML insulin lispro-aabc 200 UNT/ML Pen Injector

1,122 Medicaid prescriptions (Q1–Q4 2025) <1% of Insulin Lispro Injection prescriptions shown $2.3M gross reimbursement (before rebates) ≈ $2,012 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2380254

Sensor 3 ML insulin lispro 100 UNT/ML Pen Injector

220 Medicaid prescriptions (Q1–Q4 2025) <1% of Insulin Lispro Injection prescriptions shown $42,595 gross reimbursement (before rebates) ≈ $194 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2621571

Sensor 3 ML insulin lispro-aabc 100 UNT/ML Pen Injector

13 Medicaid prescriptions (Q1–Q4 2025) <1% of Insulin Lispro Injection prescriptions shown $9,285 gross reimbursement (before rebates) ≈ $714 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2380267

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Insulin Lispro Injection, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 20 of 102 listed Insulin Lispro Injection NDCs with Medicaid activity.

Compare Insulin Lispro Injection products

A representative set of FDA-listed product records for Insulin Lispro Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Injection
100 [IU]/mL Intravenous, Subcutaneous A-S Medication Solutions × 5 listings BLA View NDC →
100 [IU]/mL Intravenous, Subcutaneous Eli Lilly and Company × 5 listings BLA View NDC →
100 [IU]/mL Subcutaneous Eli Lilly and Company × 7 listings BLA View NDC →
200 [IU]/mL Subcutaneous Eli Lilly and Company BLA View NDC →
INSULIN LISPRO 100 U/mL Subcutaneous Remedyrepack Inc. BLA View NDC →
INSULIN LISPRO 100 U/mL Intravenous, Subcutaneous Sanofi-Aventis U.S. LLC × 2 listings BLA View NDC →
INSULIN LISPRO 100 U/mL Subcutaneous Sanofi-Aventis U.S. LLC BLA View NDC →

Showing 22 of 22 products — FDA National Drug Code Directory. See every product, package size and price: browse all 22 Insulin Lispro Injection NDCs →

Insulin Lispro Injection recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list 3 Insulin Lispro recalls since July 2021. One of them is still ongoing and is listed first. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.

Ongoing Class II Apr 11, 2023 · Sanofi-Aventis U.S. LLC
Lack of Assurance of Sterility: Malformed crimped collar seal
  • Admelog, insulin lispro injection, 100 units/mL (U-100), 3mL multi-dose vial, Rx Only, Sanofi-Aventis U.S. LLC, Bridgewater, NJ 08807 A Sanofi Company. NDC 0024-5926-05 Lots: Lot # 3F497B, EXP 12-31-2025 FDA record D-0575-2023 →
Class II Mar 12, 2024 · Completed · Eli Lilly & Company
CGMP Deviations
  • Sterile Diluent, HUMALOG U-100 (insulin lispro injection), HUMULIN R U-100 REGULAR (insulin human injection), Insulin Lispro Injection u-100, 10 mL, Use ONLY with Insulins listed on carton, Marketed… Lots: Batch number: D608951C, exp 4/10/2025 FDA record D-0445-2024 →
Class I Apr 5, 2022 · Completed · Cardinal Health Inc.
TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions due to inclement weather.
  • Humalog KwikPen, Insulin lispro injection, U-100, 100 units per mL, 5x3 mL Prefilled Pens per box, Marketed by Lilly USA, LLC, Indianapolis, IN 46285, Box NDC 0002-8799-59, Pen NDC 002-7516-59 Lots: Unknown FDA record D-0882-2022 →

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Insulin Lispro Injection RxCUI 86009 3 dose forms · 12 strengths
  2. Dose form (SCDF) Injectable Solution RxCUI 378841 In current FDA listings
    Clinical drug / strength (SCD) aabc 100 UNT/ML RxCUI 2380231 100 UNT/ML RxCUI 242120
  3. Dose form (SCDF) Pen Injector RxCUI 1652238 In current FDA listings
    Clinical drug / strength (SCD) Sensor 3 ML insulin lispro 100 UNT/ML RxCUI 2621571 Sensor 3 ML insulin lispro-aabc 100 UNT/ML RxCUI 2380267 0.5 UNT Doses 3 ML insulin lispro 100 UNT/ML RxCUI 1926331 0.5 UNT Doses 3 ML insulin lispro-aabc 100 UNT/ML RxCUI 2380265 3 ML insulin lispro 100 UNT/ML RxCUI 1652639 3 ML insulin lispro 200 UNT/ML RxCUI 1652239 3 ML insulin lispro-aabc 100 UNT/ML RxCUI 2380259 3 ML insulin lispro-aabc 200 UNT/ML RxCUI 2380254

Look up RxCUI 86009 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

💵 What Insulin Lispro Injection costs pharmacies (NADAC benchmark)

The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.

FormStrengthPharmacy acquisition benchmark
Injection, Solution · Intravenous; Subcutaneous 100 [IU]/mL $6.36 per mL NDC details & price history
Injection, Solution · Intravenous; Subcutaneous 100 U/mL $9.39 per mL NDC details & price history
Injection, Solution · Subcutaneous 100 [IU]/mL $10.16 per mL NDC details & price history
Injection, Solution · Subcutaneous INSULIN LISPRO 100 U/mL $12.11 per mL NDC details & price history
Injection, Solution · Subcutaneous 200 [IU]/mL $20.31 per mL NDC details & price history
Injection, Solution · Subcutaneous 100 U/mL $12.11 per mL NDC details & price history
Injection, Solution · Intravenous, Subcutaneous 100 [IU]/mL $6.36 per mL NDC details & price history
Injection, Solution · Intravenous, Subcutaneous INSULIN LISPRO 100 U/mL $9.39 per mL NDC details & price history
Injection, Suspension · Subcutaneous 100 [IU]/mL $8.15 per mL NDC details & price history
Why show this? Your out-of-pocket cost depends on insurance, pharmacy markup, and discounts — but the acquisition benchmark tells you whether the medication itself is inexpensive or costly, which strengths cost more per dose, and whether a cash-price quote is in a reasonable range. Each row links to the NDC-level record with its full price history.

Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.

Insulin Lispro Injection brand names

Insulin Lispro Injection is sold under 13 brand names in the FDA directory — Admelog, Humalog, Humalog Mix50/50, Humalog Mix75/25 and others. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Admelog Humalog Humalog Mix50/50 Humalog Mix75/25 Lyumjev Humalog KwikPen Humalog Junior KwikPen Humalog Tempo Pen Humalog Mix75/25 KwikPen Humalog Mix50/50 KwikPen Insulin Lispro Junior KwikPen Insulin Lispro KwikPen Sterile Diluent

Who makes Insulin Lispro Injection: manufacturers and labelers

4 companies list Insulin Lispro Injection products with the FDA. By number of product records, the largest are Eli Lilly and Company, A-S Medication Solutions, Sanofi-Aventis U.S. LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Eli Lilly and Company 13 A-S Medication Solutions 5 Sanofi-Aventis U.S. LLC 3 Remedyrepack Inc. 1

Insulin Lispro Injection drug class (RxNorm)

Insulin Lispro Injection belongs to the Insulin Analog class.

Pharmacologic class Insulin Analog
Drug family (ATC) Insulins and analogues for injection, fast-acting, Insulins and analogues for injection, intermediate-acting, Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Insulin Lispro Injection page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Jun 16, 2026
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Insulin Lispro Injection.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Insulin Lispro Injection after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
11
Finished products in the current FDA directory
22
Companies listing them (makers, repackagers, distributors)
4
FDA labeler codes behind them ⓘ
4
Linked representative label ⓘ
Eli Lilly and Company
Linked label effective
Jun 16, 2026
Composite sections available
23
Linked SPL Set ID
c8ecbd7a-0e22-4fc7-a503-faa58c1b6f3f
Linked SPL Document ID
03be5386-187a-420f-9021-55778a73eba0
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Eli Lilly and Company is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →